ClinicalTrials.gg
CompletedNCT02611024Updated Jul 9, 2025

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

A Phase 1/2 interventional study of Lurbinectedin and Irinotecan in Advanced Solid Tumors, Glioblastoma and Soft Tissue Sarcoma (Excluding GIST), sponsored by PharmaMar. Completed at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by PharmaMar · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
316
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies in Glioblastoma with a site in Spain — 10 open to participants now, 22 under way, 6 of them phase 3. Glioblastoma · Spain.

Enrollment
15th of 87
316 · median 75
Started
2016
with 4 others
Phase 1/2
20 of 94
4 open now
Registered
45th of 94
by date

Among the 94 studies in Glioblastoma with a site in Spain, this one is the 15th largest by enrollment of the 87 interventional ones that give a count, is one of 5 that started in 2016, is one of 20 in phase 1/2, and was the 45th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

10 of the 94 studies in Glioblastoma with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Glioblastoma with a site in Spain, or all of them as a file.
02

Study summary

Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.

Read the detailed description

Phase I dose escalation stage.

During the Phase I escalation stage, patients with selected advanced solid tumors will be divided into three groups: the Lurbinectedin Escalation Group, the Irinotecan Escalation Group and the Intermediate Escalation Group. Each group will have a different dose escalation scheme. A treatment cycle is defined as an interval of three weeks.

Three to six patients will be included at each dose level. If dose-limiting toxicity (DLT) occurs in less than one third of evaluable patients in each cohort, escalation can proceed to the next dose level within each group.

The MTD in each group will be the lowest dose level explored during dose escalation in which one third or more of evaluable patients develops a DLT in Cycle 1. At any dose level, if one among the first three evaluable patients has a DLT, the dose level should be expanded up to six patients. Dose escalation will be terminated once the MTD or the last dose level is reached, whichever occurs first, except if all DLTs occurring at a given dose level are related to neutropenia (i.e., febrile neutropenia, grade 4 neutropenia lasting > 3 days or neutropenic sepsis) in which case dose escalation may be resumed, starting at the same dose level and following the same original schedule but with mandatory primary G-CSF prophylaxis.

Once the MTD has been reached, a minimum of nine evaluable patients will be recruited at the immediately lower dose level (or at the last dose level if the MTD is not defined yet): this level will be confirmed as the RD if less than one third of the first nine evaluable patients develop DLT during Cycle 1.

Phase II expansion stage.

If signs of activity are observed in one or more tumor types, there will be a phase II expansion stage after the RD is defined for each group. A tumor-specific expansion cohort (or cohorts if signs of activity are observed in more than one of the permitted tumor types) at each of these RDs may include approximately 20 treated patients per tumor type. If no indication of efficacy is observed in the dose escalation phase of a specific group, then recruitment of patients into that group may be terminated.

Furthermore, one new cohort of patients with neuroendocrine neoplasms (NENs), with approximately 40 treated patients, will be included in the Phase II expansion stage of this study. Patients in this cohort will be treated at the RD determined during the Phase I escalation stage in the Lurbinectedin Escalation Group (Lurbinectedin 2.0 mg/m2 plus irinotecan 75 mg/m2 with the administration of G-CSF). These patients will be divided into two groups of 20 treated patients each:

  • Group 1 will include patients with poorly differentiated grade 3 neuroendocrine cancer (NEC) (Ki67 >20%) of gastroenteropancreatic origin or unknown primary site (excluding lung primary tumors) according to the 2019 World Health Organization (WHO) classification of tumors of the digestive system, after progression to first-line chemotherapy with a platinum-based regimen.
  • Group 2 will include patients with well differentiated grade 2 (Ki-67 3-20%) or grade 3 (Ki-67 21-55%) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) according to the 2019 WHO classification of tumors of the digestive system, after progression to no more than three prior lines of systemic therapy.

Following the finding of promising efficacy to date, two expansion cohorts in the Lurbinectedin Escalation Group will be further expanded:

  • The cohort of patients with small cell lung cancer (SCLC) will be expanded to at least 100 patients treated in second line.
  • The cohort of patients with soft tissue sarcoma (STS) will be expanded with between 25 and 80 treated patients with synovial sarcoma (a subtype of STS)

Only in these two expansion cohorts, an Independent Review Committee (IRC) will determine the response evaluation at each tumor assessment necessary to derive the best patient's response and assign the date of first documentation of response and progression/censoring according to RECIST v.1.1. Operational details for the IRC and the algorithm and its validation by an expert panel are described in detail in the IRC charter.

03

Conditions studied

  • Advanced Solid Tumors
  • Glioblastoma
  • Soft Tissue Sarcoma (Excluding GIST)
  • Endometrial Carcinoma
  • Epithelial Ovarian Carcinoma
  • Mesothelioma
  • Gastroenteropancreatic Neuroendocrine Tumor
  • SCLC
  • Gastric Carcinoma
  • Pancreatic Adenocarcinoma
  • Colorectal Carcinoma
  • Neuroendocrine Tumors

Keywords

  • Lurbinectedin
  • PM01183
  • Tumors
  • Cancer
  • Pharma Mar
  • Sarcoma
  • SCLC
  • Neuroendocrine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed and dated written prior to any specific-study procedure.
  2. Age ≥ 18 years.
  3. (ECOG) performance status (PS) ≤ 1.
  4. ≥ 3 months.
  5. or cytologically confirmed diagnosis of advanced disease of any of the following tumor types:

    For the Lurbinectedin Escalation Group and the Irinotecan Escalation Group:

    1. Glioblastoma.
    2. Soft-tissue sarcoma (excluding gastrointestinal stromal tumors [GIST]).
    3. Endometrial carcinoma.
    4. Epithelial ovarian carcinoma (including primary peritoneal disease and/or fallopian tube carcinomas and/or endometrial adenocarcinomas) regardless of platinum sensitivity.
    5. Mesothelioma.
    6. Gastroenteropancreatic neuroendocrine tumors (GEP-NET).
    7. Small cell lung cancer (SCLC).
    8. Pancreatic adenocarcinoma.
    9. Gastric carcinoma.
    10. Colorectal carcinoma (CRC).

    For the Intermediate Escalation Group:

    1. Endometrial carcinoma.
    2. SCLC.
    3. Other solid tumors may be included, if appropriate, after discussion between the Investigators and the Sponsor.

    For the Phase II expansion stage:

    1. Glioblastoma.
    2. Soft tissue sarcoma (including synovial sarcoma),
    3. Endometrial carcinoma.
    4. SCLC.
    5. Neuroendocrine tumors.

      • Group 1: Poorly differentiated grade 3 NEC (Ki-67 >20%) according to the 2019 WHO classification of tumors of the digestive system, of gastroenteropancreatic origin or unknown primary site (lung primary tumors will be excluded).
      • Group 2: Well differentiated grade 2 (Ki-67 3-20%) or grade 3 (Ki-67 21-55%) GEP-NETs according to the 2019 WHO classification of tumors of the digestive system.
  6. The number of allowed per patient will be as follows:

    For the Phase I Escalation Stage:

    No more than two prior lines of cytotoxic-containing chemotherapy regimens for advanced disease

    For the Phase II Lurbinectedin Expansion Stage:

    • For SCLC, one prior line of platinum-containing chemotherapy with/without antibodies against programmed cell death protein-1 () or programmed death ligand-1 (PD-L1).
    • For NENs,

      • In Group 1 (patients with poorly differentiated NEC of gastroenteropancreatic origin or unknown primary site, excluding lung primary tumors), one prior line of platinum-based chemotherapy; and
      • In Group 2 (patients with well differentiated GEP-NETs), no more than three prior lines of systemic therapy (that may include somatostatin analogues, chemotherapy, everolimus and/or sunitinib).
    • For all other tumor types, no more than two prior lines of cytotoxic-containing chemotherapy regimens for advanced disease.

    There is no limit for prior targeted therapy, hormonal therapy and immunotherapy (such as nivolumab).

  7. Phase II expansion stage: Tumor-specific cohort(s) at the RD:

    1. according to (RECIST) v.1.1. For patients with glioblastoma: Measurable disease according to RECIST v.1.1 and Response Assessment in Neuro-Oncology (RANO) criteria.
    2. Documented disease progression per RECIST v.1.1 during or immediately after last therapy according to any of the aforementioned criteria. For patients with glioblastoma: Documented disease progression per RECIST v.1.1 and RANO criteria.
  8. At least three weeks since the last anticancer therapy, (including immunotherapy, drugs and radiotherapy), and at least six weeks since nitrosoureas and mitomycin C (systemic).

    For biological/investigational anticancer therapies given orally, the aforementioned period of at least three weeks could be changed for one of at least five half-lives (whichever occurred first), provided that the therapy is given as single agent and not combined with other drugs. If this is not the case, this exception will not be acceptable.

    For patients with glioblastoma: at least 12 weeks since the end of radiotherapy, except if:

    1. The patient has a new lesion outside of the radiotherapy field, or
    2. The patient has undergone brain surgery to remove the tumor before study entry, and progressive disease has been confirmed histologically.

    Note: will be referred to the day of first cycle administration (Day 1), not to the day of registration (Day 0).

  9. Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ 7 days before inclusion in the trial):

    1. count ≥ 100 × 10\^9/L, ≥ 9.0 g/dL and (ANC) ≥ 2.0 × 10\^9/L.
    2. (AST) and alanine aminotransferase (ALT) ≤ 3.0 × the (ULN), even in the presence of liver .
    3. Alkaline phosphatase (ALP) ≤ 2.5 × ULN (≤ 5 × ULN if disease-related/in the case of liver metastases).
    4. Total ≤ 1.5 × ULN or direct bilirubin ≤ ULN.
    5. (INR) \< 1.5 (except if patient is on oral anticoagulation therapy).
    6. Calculated (CrCL) ≥ 30 mL/minute (using Cockcroft-Gault formula).
    7. Creatine phosphokinase (CPK) ≤ 2.5 × ULN.
    8. Albumin ≥ 3.0 g/dL*
  10. Recovery to grade ≤ 1 or to baseline from any adverse event (AE) derived from previous treatment (excluding alopecia and/or cutaneous toxicity and/or peripheral neuropathy and/or fatigue grade ≤ 2).

    • Albumin transfusion to increase the blood level in order to fulfill the inclusion criterion is strictly forbidden.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant diseases/conditions:

    1. History or presence of unstable angina, myocardial infarction, congestive heart failure, or valvular heart disease within the previous year.
    2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.
    3. Myopathy or any clinical situation that causes significant and persistent elevation of CPK (> 2.5 × in two different determinations performed one week apart).
    4. Ongoing chronic alcohol consumption or cirrhosis with score B or C. Known Gilbert disease.
    5. Active uncontrolled infection.
    6. Known (HIV) or known virus (HCV) infection or active .
    7. Any past or present chronic inflammatory colon and/or liver disease, past intestinal obstruction, pseudo or sub-occlusion or paralysis.
    8. Evident symptomatic pulmonary fibrosis or interstitial pneumonitis, pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.
    9. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study
    10. Active Coronavirus disease (COVID-19).
    11. to any of the study drugs or their .
  2. Prior treatment with lurbinectedin, trabectedin (Yondelis®) or topoisomerase I inhibitors (irinotecan, topotecan, etc.). Prior topoisomerase inhibitors (e.g., irinotecan) are only allowed in patients with colorectal carcinoma or NENs.
  3. Prior bone marrow or stem cell transplantation, or radiation therapy in more than 35% of bone marrow.
  4. Known or involvement. Glioblastoma lesions (primary or locally advanced) are eligible. Exception: patients with brain metastases are eligible provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of treatment (patients taking steroids in the process of already being tapered within two weeks prior to screening are allowed). Brain CT-scan or MRI results must be provided at baseline.
  5. Women who are pregnant or breast feeding and fertile patients (men and women) who are not using an effective method of . Women of (WOCBP) must agree to use an effective contraception method to avoid pregnancy during the course of the trial (and for at least six months after the last infusion). Fertile male patients must agree to refrain from fathering a child or donating sperm during the trial and for four months after the last infusion.
  6. Limitation of the patient's ability to comply with the treatment or follow-up protocol.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (actual)

Study arms

  • Experimental
    Lurbinectedin Escalation Group

    Irinotecan 75 mg/m\^2 as a 90-min (-5-min/+30-min) intravenous (i.v.) infusion, followed by Lurbinectedin with starting dose of 1.0 mg/m\^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min \[-5-min/+30-min\] i.v. infusion)

    Drug: Lurbinectedin · Drug: Irinotecan

  • Experimental
    Irinotecan Escalation Group

    Starting dose of Irinotecan 15 mg/m\^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 3.0 mg/m\^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min \[-5-min/+30-min\] i.v. infusion).

    Drug: Lurbinectedin · Drug: Irinotecan

  • Experimental
    Intermediate Escalation Group

    Starting dose of Irinotecan 50 mg/m\^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 2.6 mg/m\^2 as a 60-min (-5-min/+20-min) i.v. infusion. No Irinotecan dose will be administered on Day 8 in this group.

    Drug: Lurbinectedin · Drug: Irinotecan

Interventions

  • lurbinectedin (PM01183) 4 mg vials

    Also known as: PM01183

  • irinotecan 40 mg, 100 mg or 300 mg vials

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    The MTD will be the lowest dose level explored during dose escalation which one third or more of evaluable patients develops DLTs in Cycle 1. DLTs are related AEs during Cycle 1 fulfilling at least 1 of the criteria below: * Grade 4 neutropenia lasting \>3 days * Febrile neutropenia of any duration or neutropenic sepsis * Grade 4 thrombocytopenia/Grade 3 with clinically bleeding requiring a transfusion * Grade 4 ALT/AST increase/Grade 3 lasting \>14 days * Grade≥2 increased ALT/AST concomitantly with total bilirubin increase ≥2.0×ULN and normal ALP * Grade≥3 diarrhea lasting \>5 days and despite adequate corrective treatment * Grade≥3 CPK increase * Grade≥3 non-hematological related AE, excluding nausea/vomiting, hypersensitivity reactions, extravasations, grade 3 fatigue lasting \<1 week and nonclinically biochemical abnormalities * Administration delay of Cycle 2 \>15 days from the Day 22 due to any related AEs * Failure to meet the Day-8 continuation criteria for irinotecan in Cycle 1

    Time frame: 66 months

  2. Recommended Dose (RD)

    The RD will be the highest dose level explored during dose escalation in which fewer than one third of patients develop DLTs during Cycle 1. DLTs are related AEs during Cycle 1 fulfilling at least 1 of the criteria below: * Grade 4 neutropenia lasting \>3 days * Febrile neutropenia of any duration or neutropenic sepsis * Grade 4 thrombocytopenia/Grade 3 with clinically bleeding requiring a transfusion * Grade 4 ALT/AST increase/Grade 3 lasting \>14 days * Grade≥2 increased ALT/AST concomitantly with total bilirubin increase ≥2.0×ULN and normal ALP * Grade≥3 diarrhea lasting \>5 days and despite adequate corrective treatment * Grade≥3 CPK increase * Grade≥3 non-hematological related AE, excluding nausea/vomiting, hypersensitivity reactions, extravasations, grade 3 fatigue lasting \<1 week and nonclinically biochemical abnormalities * Administration delay of Cycle 2 \>15 days from the Day 22 due to any related AEs * Failure to meet the Day-8 continuation criteria for irinotecan in Cycle 1

    Time frame: 66 months

  3. Response Rate

    Phase II Expansion Stage: Efficacy Response rate is a percentage of patients with any response: partial response or complete response. Antitumor activity will be measured according to RECIST v.1.1. * An increase of ≥20% from the baseline or new lesion appears represents progressive disease. * A decrease in the sum of target disease of ≥30% represents partial response. * Stable disease lies between partial response and progressive disease. * Complete response is the disappearance of all lesions with nodes measuring \<10 mm and normal tumour markers Patients included in the tumor-specific expansion cohort(s) at the RD for each group, and in the new cohort of patients with NENs, must be evaluable per RECIST v.1.1 (including ovarian cancer patients). Specifically, patients with glioblastoma must be evaluated per RECIST v.1.1 and RANO criteria. A patient evaluable for efficacy should have received at least one complete dose of lurbinectedin and irinotecan.

    Time frame: At least six weeks after treatment initiation, up to 66 months

Secondary outcomes

  1. Safety evaluation

    AEs will be graded according to the NCI-CTCAE v.4.

    Time frame: Since start of the treatment until 30 days after the last administration of study treatment; or until start of a new antitumor therapy or death

  2. Peak Plasma Concentration (Cmax)

    Pharmacokinetic Outcome Measures

    Time frame: 66 months

  3. Area under the plasma concentration versus time curve (AUC)

    Pharmacokinetic Outcome Measures

    Time frame: 66 months

  4. Volume of distribution based on the terminal half-life (Vz)

    Pharmacokinetic Outcome Measures

    Time frame: 66 months

  5. Volume of distribution at steady state (Vss)

    Pharmacokinetic Outcome Measures

    Time frame: 66 months

  6. Clearance (CL)

    Pharmacokinetic Outcome Measures

    Time frame: 66 months

  7. Half-life (t1/2)

    Pharmacokinetic Outcome Measures

    Time frame: 66 months

  8. Duration of response

    Evaluable and measurable as per RECIST v.1.1 or RANO for Glioblastoma patients

    Time frame: Time from date when response criteria are fulfilled to the first date when progression disease, recurrence or death, until 18 months after the inclusion of the last evaluable patient in the study (end of study), whichever occurs

  9. Progression-free Survival

    Time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death has not occurred at the time of the analysis, the Progression-free Survival (PFS) will be censored on the date of last tumor evaluation.

    Time frame: From the date of first infusion of study treatment to the date of progression or death or until 18 months after the inclusion of the last evaluable patient in the study (end of study), whichever occurs first.

  10. Overall Survival

    Time from the date of first infusion of study treatment to the date of death (due to any cause). Patients with no documented death will be censored at the last date they are known to be alive.

    Time frame: From the date of first infusion of study treatment to the date or death or until 18 months after the inclusion of the last evaluable patient in the study (end of study), whichever occurs first.

07

Study locations

23 sites
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Massachusetts General Hospital -
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Centre Léon Bérard
    Lyon, 69373, France
  • Institut Gustave Roussy
    Villejuif, 94800, France
  • Helios Kilinikum Bad Saarow
    Bad Saarow, 15526, Germany
  • Helios Klinikum Berlin Buch
    Berlin, 13125, Germany
  • Campus Biomedico
    Roma, 00128, Italy
  • IRCCS Fondazione Candiolo (Turin)
    Torino, 10060, Italy
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Univeristari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Puerta de Hierro
    Madrid, 28022, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
  • Hospital Clínico Universitario de Santiago
    Santiago de Compostela, 15706, Spain
  • Hospital Virgen Del Rocio
    Seville, 41013, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Inselspital Bern - Medizinische Onkologie
    Bern, CH 3010, Switzerland
08

References and documents

Publications

  • Falcon A, Cote GM, Molina-Cerrillo J, Le Cesne A, Rocha P, Bockorny B, Paez D, Martin-Broto J, Chawla SP, Martinez S, Kahatt C, Alfaro V, Siguero M, Jimenez J, Custodio A, Alonso-Orduna V, Lopez C, Kollar A, Soto-Castillo JJ, Paz-Ares L. Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors. Invest New Drugs. 2026 May 4. doi: 10.1007/s10637-026-01616-0. Online ahead of print. PubMed 42081171 ↗
  • Ponce S, Ruiz-Torres M, Falcon A, Cote GM, Bernabe R, Lin JJ, Coya JM, Jimenez-Munoz M, Fernandez-Puyuelo P, Sanchez A, Zugazagoitia J, Ucero A, Baena J, Bote de Cabo H, Herrera M, Torres-Jimenez J, Zurera M, Kahatt C, Lopez-Vilarino JA, Martinez S, Siguero M, Malumbres M, Ferrer I, Paz-Ares L. Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC. J Thorac Oncol. 2026 Mar 4:103654. doi: 10.1016/j.jtho.2026.103654. Online ahead of print. PubMed 41791703 ↗
  • Falcon A, Ponce S, Cote GM, Gil A, Lin JJ, Bockorny B, Martinez J, Kahatt C, Martinez S, Zubiaur P, Siguero M, Cullell-Young M, Jimenez J, Zugazagoitia J, Paz-Ares L. Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors. Invest New Drugs. 2025 Aug;43(4):955-967. doi: 10.1007/s10637-025-01583-y. Epub 2025 Sep 18. PubMed 40963055 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Jul 2025, 109 months.

Of 53 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's 109 months is above that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2015
First posted
Nov 20, 2015
StartActual
May 6, 2016
Primary completionActual
Jul 1, 2025
CompletionActual
Jul 1, 2025
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02611024
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Nov 20, 2015
Start date
May 6, 2016
Primary completion
Jul 1, 2025
Completion
Jul 1, 2025
Last update
Jul 9, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion